ClinicalTrials.gg
CompletedNCT07284654Updated Oct 16, 2026

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

A Phase 3 interventional study of 31 valent pneumococcal conjugate vaccine and PCV20 in Pneumococcal Disease, sponsored by Vaxcyte, Inc.. Completed at 30 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Vaxcyte, Inc. · Phase 3, Interventional, and Prevention

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,049
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Pneumococcal Infections with a site in United States — 6 open to participants now, 12 under way, 6 of them phase 3. Pneumococcal Infections · United States.

Enrollment
3rd of 77
4,049 · median 605
Started
2025
with 1 other
Phase 3
39 of 83
4 open now
Registered
75th of 83
by date
Lead sponsor
5 of 83
Vaxcyte, Inc.

Among the 83 studies in Pneumococcal Infections with a site in United States, this one is the 3rd largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2025, is one of 39 in phase 3, and was the 75th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

6 of the 83 studies in Pneumococcal Infections with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Pneumococcal Infections with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.

03

Conditions studied

  • Pneumococcal Disease

Keywords

  • 31 Valent PCV
  • Pneumonia
  • Pneumococcal Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age (inclusive) at the time of randomization into the study.
  • Able and willing to complete the process.
  • Available for clinical follow-up through the last study visit.
  • In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator).
  • Willing to have blood samples collected and used for research purposes.
  • Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process.
  • Female participants of , defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable . Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method.
  • Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary).

Exclusion criteria

Exclusion Criteria:

  • History of invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age.
  • Previous receipt of any licensed or pneumococcal vaccine at any age.
  • Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
  • Receipt of any within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1.
  • Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened).
  • Current diagnosis of , , or .
  • History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination.
  • Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation.
  • Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency.
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or disorder requiring special precautions) resulting in bruising or bleeding difficulties with IM injections or blood draws.
  • Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study.
  • Is currently receiving or immune-modifying therapy, including systemic (this includes ≥3 months of prednisone equivalent from 5 to \<10 mg/day and ≥2 weeks of prednisone equivalent ≥10 mg/day).
  • Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccination.
  • History of ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Any medical, psychiatric, or social condition that in the judgment of the Investigator is a to protocol participation or impairs a subject's ability to give .
  • Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,049 participants (actual)

Study arms

  • Experimental
    Cohort 1 (VAX-31), participant ≥ 50 years of age

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Biological: 31 valent pneumococcal conjugate vaccine

  • Active comparator
    Cohort 1 (PCV21), participant ≥ 50 years of age

    Participants will receive a single dose of PCV21 (Capvaxive) administered via intramuscular injection at Day 1

    Biological: PCV21

  • Active comparator
    Cohort 1 (PCV20), participant ≥ 50 years of age

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Biological: PCV20

  • Experimental
    Cohort 2 (VAX-31), participant 18-49 years of age

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Biological: 31 valent pneumococcal conjugate vaccine

  • Active comparator
    Cohort 2 (PCV20), participant 18-49 years of age

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Biological: PCV20

Interventions

06

What researchers measure

Primary outcomes

  1. Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and above

    Time frame: 1 month after vaccination

  2. Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)

    Time frame: up to 7 days after vaccination

  3. Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)

    Time frame: up to 7 days after vaccination

  4. Percentage of subjects reporting unsolicited AE

    Time frame: up to 31 days after vaccination

  5. Percentage of subjects reporting serious adverse events (SAE), new onset of chronic illness (NOCI), and medically attended adverse events (MAAE)

    Time frame: up to 6 Months after vaccination

  6. Serotype-specific OPA geometric mean titers (GMT) in 18 to 49 year olds and 50 to 64 year olds

    Time frame: 1 month after vaccination

Secondary outcomes

  1. Serotype-specific IgG geometric mean concentrations (GMC) in 50 year olds and above

    Time frame: 1 month after vaccination

  2. Serotype-specific IgG GMC in 18 to 49 year olds and 50 to 64 year olds

    Time frame: 1 month after vaccination

07

Study locations

30 sites
  • Accel Research Site - Achieve - Birmingham - ERN
    Birmingham, Alabama 35216, United States
  • Center for Indigenous Health - Chinle - Johns Hopkins Project
    Chinle, Arizona 86503, United States
  • Center for Indigineous Health - Whiteriver - John Hopkins Project
    Whiteriver, Arizona 85941, United States
  • Clinical Innovations Trials - Riverside - CenExel
    Riverside, California 92506, United States
  • Research Centers of America - Hollywood - CenExel
    Hollywood, Florida 33024, United States
  • Health Awareness - Jupiter - ERN
    Jupiter, Florida 33458, United States
  • Suncoast Research Group LLC
    Miami, Florida 33135, United States
  • Precision Clinical Research - Sunrise
    Sunrise, Florida 33351, United States
  • Clinical Research Atlanta - Headlands
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research)
    Valparaiso, Indiana 46383, United States
  • Johnson County Clin-Trials - JCCT
    Lenexa, Kansas 66219, United States
  • Alliance for Multispecialty Research, LLC - West Wichita
    Wichita, Kansas 67207, United States
  • DelRicht Clinical Research, LLC - New Orleans
    New Orleans, Louisiana 70115, United States
  • Headlands Research - Detroit - Headlands
    Southfield, Michigan 48034, United States
  • DelRicht Research, LLC - Gulfport
    Gulfport, Mississippi 39503, United States
  • Sky Integrative Medical Center - SKYCRNG
    Ridgeland, Mississippi 39157, United States
  • Alliance for Multispecialty Research, LLC - Kansas City
    Kansas City, Missouri 64114, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Advanced Memory Research Institute - CenExe
    Toms River, New Jersey 08755, United States
  • Center for Indigineous Health - Gallup - John Hopkins Project
    Gallup, New Mexico 87301, United States
  • Center for Indigineous Health - Shiprock - John Hopkins Project
    Shiprock, New Mexico 87420, United States
  • Rochester Clinical Research - ATLAS - Rochester
    Rochester, New York 14609, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73072, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Coastal Carolina Research Center - Alcanza - HyperCore
    North Charleston, South Carolina 29405, United States
  • Flourish Research - San Antonio
    San Antonio, Texas 78229, United States
  • DM Clinical Research - Sugarland
    Sugar Land, Texas 77478, United States
  • JBR Clinical Research - CenExel JBR
    Salt Lake City, Utah 84107, United States
  • Charlottesville Medical Research Center - Alcanza - HyperCore
    Charlottesville, Virginia 22911, United States
08

References and documents

Individual participant data

Plan to share: Yes — Vaxcyte is committed to providing access to anonymized data from the company's clinical trials for the purpose of legitimate scientific research. Requests for data may be addressed to datasharing@vaxcyte.com. Requests must be accompanied by a detailed analysis plan and will be reviewed for scientific validity. Data will be made available after initial product approval. Sharing of data may require execution of a data-sharing agreement.

Supporting information: Study protocol

Time frame: Individual participant data will be shared after deidentification and made available starting 6 months after initial product approval.

Access criteria: Criteria will depend on the specific proposal received and may include qualification of the scientific researchers, potential contribution to the research field, scientific rigor of statistical and analytical methods, and other criteria appropriate for the proposal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Sep 2026, 9 months.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 9 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jan 2027 → Sep 2026 and completion Jan 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 16, 2025
StartActual
Dec 1, 2025
Primary completionActual
Sep 17, 2026was Jan 2027
CompletionActual
Sep 17, 2026was Jan 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
Jan 2027→Sep 17, 2026 (actual)
Oct 16, 2026
Study completion
Jan 2027→Sep 17, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Primary completion Jan 2027→Sep 17, 2026 (now actual)
    Study completion Jan 2027→Sep 17, 2026 (now actual)
    + 3 other changes: index terms, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284654
Lead sponsor
Vaxcyte, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 1, 2025
Primary completion
Sep 17, 2026
Completion
Sep 17, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion